| 发明名称 |
Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2 |
| 摘要 |
<p>The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.</p> |
| 申请公布号 |
AU2010319327(B2) |
申请公布日期 |
2015.08.13 |
| 申请号 |
AU20100319327 |
申请日期 |
2010.11.12 |
| 申请人 |
FIVE PRIME THERAPEUTICS, INC. |
发明人 |
HARDING, THOMAS;KAVANAUGH, MICHAEL W. |
| 分类号 |
A61K38/18 |
主分类号 |
A61K38/18 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
|
| 地址 |
|
